Literature DB >> 28723417

Long-term morphine delivery via slow release morphine pellets or osmotic pumps: Plasma concentration, analgesia, and naloxone-precipitated withdrawal.

Virginia D McLane1, Ivy Bergquist2, James Cormier2, Deborah J Barlow2, Karen L Houseknecht3, Edward J Bilsky4, Ling Cao3.   

Abstract

AIMS: Slow-release morphine sulfate pellets and osmotic pumps are common routes of chronic morphine delivery in mouse models, but direct comparisons of these drug delivery systems are lacking. In this study, we assessed the efficacy of slow-release pellets versus osmotic pumps in delivering morphine to adult mice. MAIN
METHODS: Male C57BL/6NCr mice (8weeksold) were implanted subcutaneously with slow-release pellets (25mg morphine sulfate) or osmotic pumps (64mg/mL, 1.0μL/h). Plasma morphine concentrations were quantified via LC-MS/MS, analgesic efficacy was determined by tail flick assay, and dependence was assessed with naloxone-precipitated withdrawal behaviors (jumping) and physiological effects (excretion, weight loss). KEY
FINDINGS: Morphine pellets delivered significantly higher plasma drug concentrations compared to osmotic pumps, which were limited by the solubility of the morphine sulfate and pump volume/flow rate. Within 96h post-implantation, plasma morphine concentrations were indistinguishable in pellet vs. pump-treated samples. While osmotic pump did not have an antinociceptive effect in the tail flick assay, pumps and pellets induced comparable dependence symptoms (naloxone-precipitated jumping behavior) from 24-72h post-implantation. SIGNIFICANCE: In this study, we compared slow-release morphine pellets to osmotic minipumps for morphine delivery in mice. We found that osmotic pumps and subcutaneous morphine sulfate pellets yielded significantly different pharmacokinetics over a 7-day period, and as a result significantly different antinociceptive efficacy. Nonetheless, both delivery methods induced dependence as measured by naloxone-precipitated withdrawal.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug delivery; Morphine; Opiates; Opioids; Osmotic pumps; Slow-release morphine pellets

Mesh:

Substances:

Year:  2017        PMID: 28723417      PMCID: PMC5577921          DOI: 10.1016/j.lfs.2017.07.016

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  47 in total

1.  Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence.

Authors:  H Ueda; M Inoue; H Takeshima; Y Iwasawa
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Relationship of brain morphine levels to analgesic activity in acutely treated mice and rats and in pellet implanted mice.

Authors:  G A Patrick; W L Dewey; T C Spaulding; L S Harris
Journal:  J Pharmacol Exp Ther       Date:  1975-06       Impact factor: 4.030

Review 3.  Major increases in opioid analgesic abuse in the United States: concerns and strategies.

Authors:  Wilson M Compton; Nora D Volkow
Journal:  Drug Alcohol Depend       Date:  2005-07-14       Impact factor: 4.492

4.  Lack of Evidence for Benefit From Long-term Use of Opioid Analgesics for Patients With Neuropathy.

Authors:  Nora D Volkow; Walter Koroshetz
Journal:  JAMA Neurol       Date:  2017-07-01       Impact factor: 18.302

Review 5.  Constipation: Advances in Diagnosis and Treatment.

Authors:  Arnold Wald
Journal:  JAMA       Date:  2016-01-12       Impact factor: 56.272

6.  Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord.

Authors:  U Arvidsson; M Riedl; S Chakrabarti; J H Lee; A H Nakano; R J Dado; H H Loh; P Y Law; M W Wessendorf; R Elde
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

7.  The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the mu-opioid receptor.

Authors:  Jinghua Wang; Richard Charboneau; Sudha Balasubramanian; Roderick A Barke; Horace H Loh; Sabita Roy
Journal:  J Leukoc Biol       Date:  2002-05       Impact factor: 4.962

8.  Opioid receptor regulation in mice.

Authors:  B C Yoburn; B Billings; A Duttaroy
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

9.  Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.

Authors:  Mohit Pawar; Priyank Kumar; Soujanya Sunkaraneni; Sunil Sirohi; Ellen A Walker; Byron C Yoburn
Journal:  Eur J Pharmacol       Date:  2007-02-08       Impact factor: 4.432

10.  Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia.

Authors:  Gregory Corder; Vivianne L Tawfik; Dong Wang; Elizabeth I Sypek; Sarah A Low; Jasmine R Dickinson; Chaudy Sotoudeh; J David Clark; Ben A Barres; Christopher J Bohlen; Grégory Scherrer
Journal:  Nat Med       Date:  2017-01-16       Impact factor: 53.440

View more
  3 in total

1.  Different Roles of Beclin1 in the Interaction Between Glia and Neurons after Exposure to Morphine and the HIV- Trans-Activator of Transcription (Tat) Protein.

Authors:  Jessica Lapierre; Mohan K M Karuppan; Marissa Perry; Myosotys Rodriguez; Nazira El-Hage
Journal:  J Neuroimmune Pharmacol       Date:  2021-11-05       Impact factor: 7.285

2.  Morphine Accumulates in the Retina Following Chronic Systemic Administration.

Authors:  Nikolas Bergum; Casey-Tyler Berezin; Gregory Dooley; Jozsef Vigh
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-25

3.  Role of β-arrestin-2 in short- and long-term opioid tolerance in the dorsal root ganglia.

Authors:  Karan H Muchhala; Joanna C Jacob; William L Dewey; Hamid I Akbarali
Journal:  Eur J Pharmacol       Date:  2021-03-08       Impact factor: 4.432

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.